Kornimate/medical-research-clean huggingface dataset:
the feasibility and advantages of painless indwelling catheter in uniportal vats lobectomy of lung cancer

Conditions: Urethral Catheter; Complications

Summary: this study is a prospective cohort study.the main study content is the feasibility and advantages of painless indwelling catheter in perioperative period of uniportal video-assisted thoracoscopic surgery in lobectomy of lung cancer,divided into exposed and non-exposed groups.the exposed group was painless indwelled urethral catheter, the non-exposed group was indwelled urethral catheter routinely.

this study is a prospective cohort study.the main study content is the feasibility and advantages of painless indwelling catheter in perioperative period of uniportal video-assisted thoracoscopic surgery in radical resection of lung cancer,divided into exposed and non-exposed groups,divided into exposed and non-exposed groups.communicating with the surgeon and patients who meet the inclusion criteria, decide whether to enter the exposed or non-exposed group.the exposed group was painless indwelled urethral catheter, the non-exposed group was indwelled urethral catheter routinely.by collecting personal information of two groups of patients and the corresponding observation indicators to analyze whether the painless indwelling urethral catheters in lobectomy of lung cancer is more beneficial than the indwelled urethral catheter routinely in lobectomy of lung cancer, and it is safe and feasible.

Eligibility criteria:
inclusion criteria: 1.18 to 75-year old patient with lung cancer who is eligible for uniportal video-assisted thoracoscopic surgery in lobectomy. 2.the result of rapid pathology is primary lung cancer. 3.electrocardiogram, pulmonary function, color doppler echocardiography, arteriovenous color doppler ultrasound and other preoperative examination results are normal. 4.the patient agreed to participate in the study and signed the informed consent form. exclusion criteria: 1. patients have severe urinary system diseases (medium-to-severe bph, urethral stricture, urinary calculi, infections, tumors, etc.) ,and/or have undergone abdominal and pelvic surgery before surgery. 2. there is a potential infection before surgery. 3. heart and lung serious organic diseases. 4. combined thoracic adhesions, patients with severe coagulation insufficiency. 5. the time of anesthesia is more than 4 hours. -

Keywords: painless indwelling urethral catheter uniportal video-assisted thoracoscopic surgery lobectomy lung cancer
vitamin d levels and postoperative hypocalcemia after total thyroidectomy

Conditions: Hypocalcemia; Hypoparathyroidism; Vitamin D Deficiency; Thyroidectomy

Summary: hypocalcemia is one of the most frequent complications of total thyroidectomy, a procedure used for benign as well as malignant conditions of the thyroid gland. postoperative hypocalcemia is usually caused by hypoparathyroidism. vitamin d is implicated in calcium metabolism as it increases intestinal calcium transport and regulates parathormone production. aim of the present study is to evaluate preoperative vitamin d levels as a prognostic factor for postoperative hypocalcemia and hypoparathyroidism.


Eligibility criteria:
inclusion criteria: 1. patient is over 18 years old 2. patient scheduled for total thyroidectomy 3. patient signs and dates a written informed consent form (icf) and indicates an understanding of the study procedures exclusion criteria: 1. primary hyperparathyroidism 2. primary hypoparathyroidism 3. chronic renal failure 4. hypoalbuminemia 5. neck irradiation 6. systematic diseases (e.g., infections) 7. thyroid or parathyroid cancer 8. osteoporosis 9. drugs that influence calcium metabolism (vitamin d analogues, oral calcium supplements, biphosphonates, teriparatide, thiazide diuretics)

Keywords: hypocalcemia hypoparathyroidism vitamin d deficiency total thyroidectomy calcium pth
vascular closure with novel external compression device: the locket study

Conditions: Atrial Fibrillation; Hemostasis

Summary: single center, retrospective review study comparing figure of eight suture to locket, enrolling approximately 70 patients.

the volume of catheter ablation procedures for the treatment of atrial fibrillation and other arrhythmias are on the rise in the united states and worldwide. despite refinement in ablation tools and techniques which has led to a significant decline in complication rates, achieving vascular hemostasis following femoral access with large bore sheaths remains a challenge. manual compression (mc) the current standard of care, requires bedrest, often up to 8 hours. this prolonged bedrest is associated with longer length of stay and at times complications from indwelling catheters. other methods of vascular closure include figure-of-eight (f-8) a, subcutaneous suture or z-stitch or fellow's stitch has been evaluated as a means to achieve homeostasis following major cardiovascular procedures. one pooled meta-analysis of six studies including 982 patients demonstrated that f-8 is safe and effective means of achieving hemostasis. in comparison to mc time to hemostasis was significantly lower and overall access site complications like hematoma, bleeding was also noted to be lower in f-8 group. in recent years, invasive, vascular closure devices have become popular. however, results continue to suggest that the risk versus benefit has not been definitively demonstrated. locket is a new suture retention device designed to closely mimic manual compression without the need for a healthcare professional to stand bedside.

Eligibility criteria:
inclusion criteria: all participants must meet the following criteria to be included in this study. * subjects must be at least 18 years of age. * subjects underwent atrial fibrillation radiofrequency ablation procedure. * subjects must have undergone f-8 or locket for venous closure. exclusion criteria: if a subject meet any of the following criteria will be excluded from study participation. * subjects under the age of 18. * subject's electrophysiology procedure is not planned to access the left atrium or ventricle. * subjects in which f-8 or a locket was not used. * if the ep physician detected a formed hematoma prior to venous closure, that patient will be excluded from the study.
mulligan blr versus mulligan tslr versus neural mobilization n patient with lumber radiculopathy

Conditions: Lumbar Radiculopathy

Summary: the goal of this study is to compare the effectiveness of mulligan traction straight leg raise and mulligan's bent leg rise and neural mobilization to conventional therapies in order to assess which treatment is more successful in treating lumbar radiculopathy-related dysfunction.

after the synopsis is approved, randomized control trial study will be performed at riphah international university faisalabad. the patients will be enrolled using a targeted sampling method. patients would be chosen based on pre-established inclusion and exclusion requirements. for this analysis, a sample size estimate shows that 30 randomly selected male or females (18 yrs - 65 yrs) who match the selection criteria will be needed. a basic random sample of 30 lumbar radiculopathy patients was used in an experimental trial. they were divided into three groups of ten people: group a received neural mobilization with conventional therapy, group b received mulligan's bent leg rise with conventional therapy, and group c received mulligan's traction straight leg raise with conventional therapy for six months. numeric pain rating scale, passive straight leg raise, goniometer, and modified oswestry low back pain questionnaire will be used as outcome tests. after the sixth week, the pre-treatment and post-treatment results will be compared. each patient will be asked to give their informed consent. statistical package of social sciences version 20 can be used for data entry and analysis.

Eligibility criteria:
inclusion criteria: * between the ages of 18 and 65, all genders * positive slump measure of lumbar specific nerve bias, * mild to moderate irritation on a numeric pain level scale of less than seven, * unilateral radiculopathy in the distribution of a single nerve with a favourable slr, * prone knee bent test; positve test, * hypoaesthesia in a specific dermatome of the unilateral lower limb, accompanied by reduced mobility * the result of the deep tendon (knee jerk, ankle jerk). exclusion criteria: * individuals with gradually occurring neurological problems * trauma, cancer, and constitutional symptoms are indeed red flags (fever, malaise, weight loss). * hip and knee fractures are common. * lower-extremity dislocations. * hamstring strains. * joint hypermobility of the lower limb. * muscle imbalance in lower limb * nerve lesions in the lower extremity. * subjects who have had low back pain in the previous two months. * hip flexion rom was greater than 100 degrees for the straight knee. * neurological defects. * metal bolts, plates, or screws in the femur.

Keywords: mulligan technique mulligan traction neural mobilization bent leg raise randomized control trial straight leg raise radiculopathy
impact of secukinumab on clinical and patient reported outcomes in patients with psoriasis

Conditions: Psoriasis

Summary: the study was conducted to describe the demographics, disease characteristics, disease severity, comorbidities and patient reported outcomes at baseline and follow-up periods among adult patients diagnosed with pso in corevitas' pso registry under routine medical care initiating secukinumab (sec).

this is a retrospective analysis of a prospective observational cohort using corevitas' pso registry of adult pso patients. this study describes clinical and patient reported outcomes among adult patients initiating secukinumab (sec). biologic experienced and naïve patients are examined separately. this study also describes changes in clinical and patient reported outcomes over time. corevitas' psoriasis registry is a prospective, observational cohort of adult pso patients starting systemic therapy, launched in april 2015 with sites in the us and canada. data collection occurs every \~6 months at routine dermatology visits. this study included us pso patients who initiated secukinumab at or after enrollment and had a subsequent 6- and/or 12-month follow-up visit (apr 2015 to dec 2020).the index date is defined as the date of the first sec initiation at or after enrollment.

Eligibility criteria:
inclusion criteria: the patient must: * have been diagnosed with pso by a dermatologist. * be at least 18 years of age. * be willing and able to provide written informed consent for participation in the registry. * have started on or switched to an eligible systemic pso treatment at enrollment1 or within the previous 12 months of the date of enrollment. exclusion criteria: * patient is participating in or planning to participate in an interventional clinical trial with a nonmarketed or marketed investigational drug (i.e. phase i-iv drug trial).
single dose study to assess efficacy and safety of 4 doses of las100977 in chronic obstructive pulmonary disease (copd) population

Conditions: Chronic Obstructive Pulmonary Disease (COPD)

Summary: the purpose of this study is to evaluate the pharmacodynamics (bronchodilation) of single doses of inhaled las100977 in copd patients.


Eligibility criteria:
inclusion criteria: 1. males and non-pregnant, non-lactating females aged 40 or older. 2. patients with a clinical diagnosis of copd, according to the gold guidelines and stable airway obstruction. 3. patients with a post-salbutamol fev1 equal to or greater than 30% of the predicted value and less than 80% of the predicted value 4. post-salbutamol fev1/fvc \< 70% at screening visit. 5. pre-dose fev1 value of first treatment period within the range of 80-120% of the fev1 measured at screening prior to salbutamol inhalation. 6. current, or ex-cigarette smokers (former) with a smoking history of at least 10 pack-years. 7. patients whose copd symptoms at the time of randomisation are stable compared to the screening visit, according to the investigator's medical judgment. exclusion criteria: 1. history or current diagnosis of asthma. 2. a respiratory tract infection or copd exacerbation in the six weeks prior to the screening visit. 3. patients who have been hospitalised for an acute copd exacerbation in the 3 months prior to screening visit. 4. clinically significant respiratory conditions other than copd condition. 5. clinically significant cardiovascular conditions. 6. patients unable to properly use a dry powder or pmdi inhaler device or unable to perform acceptable spirometry. 7. clinically relevant abnormalities laboratory, ecg parameters or physical examination results at the screening evaluation that in the investigator's opinion, preclude study participation. 8. patients who intend to use any concomitant medication not permitted by this protocol or who have not undergone the required washout period for a particular prohibited medication.

Keywords: copd
chloroquine as a modulator of t cell immune activation

Conditions: HIV

Summary: this study will evaluate the effect of chloroquine in individuals infected with hiv. researchers will aim to determine if chloroquine treatment in participants whose viral loads are suppressed on combination antiretroviral therapy (art), results in improved immune activation and cd4 cell recovery. the study will recruit 20 individuals and will last approximately 44 weeks. eligible participants will receive an oral dose of chloroquine (250 mg) once daily from week 8 through week 32. all participants will be asked to have rectal biopsy samples (week 0 and week 32) to study t cell immune activation in the mucosa rectal site.

clinical data has identified chloroquine as a potential modulator of immune activation. the study's dose of chloroquine is the same as the dose recommended for patients having autoimmune diseases. in these autoimmune cases, a daily dose of chloroquine at 250 mg for 12 weeks has shown improvement in symptoms and decreases in inflammatory cytokines synthesis and a reduction in tlr -mediated immune activation. study findings could help provide information about where and under what circumstances chloroquine treatment may reduce t cell activation and help restore circulating cd4 t cells.

Eligibility criteria:
inclusion criteria: * documented hiv infection by western blot, eia assays or viral load assay. * aged between 18 and 65 years. * viral load less than 50 copies per ml for at least the previous 36 weeks. * cd4 cell count less than or equal to 350 cells per litre. * on stable art * vital signs, physical examination and laboratory results do not exhibit evidence diseases such as advanced cirrhosis or advanced liver * karnofsky performance status greater than or equal to 80 per cent. * participant does not require and agrees not to take, for the duration of the study, any medication that is contraindicated with chloroquine. * able to give informed consent. exclusion criteria: * active aids events in the last 3 months * co-infection with active hepatitis b or c virus. * current use or use within four weeks prior to the baseline visit, of cytotoxic agents, systemic corticosteroids or any immuno-modulatory agents. * current use within four weeks prior to the chloroquine therapy the following medications: methadone, chlorpromazine, cimetidine, cyclosporin, methotrexate and penicillanime. * psychiatric or cognitive disturbance or illness that could preclude compliance with the study. * patient with clinically significant hemophilia and von-willebrand disease and any severe bleeding disorder. * experimental hiv immune based therapy within 6 months of screening visit. * allergic reaction to chloroquine. * a history of retinitis or any retinal problem. * subjects with g6pd deficiency, porphyria, psoriasis, cirrhosis, hearing deficiency (including tinnitus), myopathy and cardiomyopathy. * pregnant and breast-feeding women.

Keywords: chloroquine t cell immune activation cd4 recovery hiv
real world evidence for the cycle of neoadjuvant chemotherapy in gastric cancer with shared decision making

Conditions: Gastric Cancer

Summary: the purpose of the study is to evaluate the maximal cycle of effective neoadjuvant chemotherapy for resectable gastric cancer, to determine what is the best cycle of neoadjuvant chemotherapy for the patients who receive neoadjuvant chemotherapy.

the study is a non-randomized clinical trial. the protocol has been approved by the ethics committee of beijing cancer hospital. mri and enhanced ct are used to evaluate the clinical response of the tumor. the primary endpoint is the maximal cycle of effective neoadjuvant chemotherapy for resectable gastric cancer.

Eligibility criteria:
inclusion criteria: 1. histologically proven adenocarcinoma of the stomach 2. clinical ct2n+m0,or ct3-4a/n+m0 disease, confirmed by upper gastrointestinal endoscopy and abdominal computed tomography (ct) and mri and laparoscopy. 3. receive neoadjuvant chemotherapy in clinical exclusion criteria: 1. contraindication for chemotherapy 2. contraindication for surgery 3. clinically apparent distant metastasis

Keywords: shared decision making neoadjuvant chemotherapy cycle mri clinical response
combined active treatment in type 2 diabetes with nash

Conditions: Type 2 Diabetes; Non-alcoholic Steatohepatitis (NASH); Non-alcoholic Fatty Liver Disease (NAFLD)

Summary: the aim of this multicentre, prospective, placebo-controlled, double-blind, randomized, 3-arm parallel group, interventional study is to assess for the first time the effects of either a combined therapy with the antihyperglycemic drugs semaglutide and empagliflozin or empagliflozin monotherapy compared to placebo as potential treatments for non-alcoholic steatohepatitis (nash) in patients with type 2 diabetes.

obesity and type 2 diabetes (t2d) are tightly associated with non-alcoholic fatty liver disease (nafld), which in turn predicts the development of t2d and cardiovascular disease. up to 80% of nafld patients with t2d have nash and the presence of t2d is an independent risk factor for more-advanced fibrosis, higher rate of fibrosis progression, and increased mortality. liver-related mortality is increased 10-fold in nash patients compared with the general population. in addition, people with nash are at an excessive risk of cardiovascular morbidity and mortality. currently, there are no established pharmacotherapies for nash patients with t2d. the aim of this trial is to evaluate efficacy of a combined treatment with semaglutide 1 mg/week (glp1ra) and empagliflozin 10 mg/d (sglt2i) or ii) empagliflozin 10 mg/d monotherapy by means of histological resolution of nash in t2d patients without progression of fibrosis after 48 weeks treatment. to confirm a histological diagnosis of nash and proof efficacy of treatment, a liver biopsy will be performed prior to screening as well as at the end of treatment phase.

Eligibility criteria:
inclusion criteria: * diagnosis of t2d and nash with fibrosis stage f1-f3 * age between 25 and 75 years * hba1c ≤ 9.5% * obtained written informed consent exclusion criteria: * contraindications on liver biopsy * evidence of cirrhosis on liver biopsy * liver disease of other etiology including chronic viral hepatitis (b or c), alcohol abuse, hemochromatosis, alpha-1 antitrypsin deficiency, autoimmune hepatitis, wilson's disease, primary sclerosing cholangitis or primary biliary cirrhosis, or liver cirrhosis of any etiology * history of ketoacidosis * alcohol consumption \>30 g/d for males and \>20 g/d for females * past (≥5 years) or current history of alcohol or drug abuse and/or psychiatric disease including severe depression necessitating pharmacological treatment * medications that may induce steatosis:tamoxifen, raloxifene, oral glucocorticoids or chloroquine * planned pregnancy, pregnant or lactating women, positive pregnancy test, and woman of childbearing potential not using two adequate methods of contraception, including a barrier method and a highly efficacious non-barrier method

Keywords: type 2 diabetes non-alcoholic steatohepatitis (nash) non-alcoholic fatty liver disease (nafld) fatty liver diabetes mellitus empagliflozin semaglutide
plasma saa1 levels in predicting response to radiotherapy-induced oral mucositis

Conditions: Nasopharyngeal Carcinoma; Head and Neck Cancer; Radiotherapy-induced Oral Mucositis; Biomarker

Summary: head and neck squamous cell carcinoma (scc) is the sixth most common cancer worldwide, with more than 700,000 new cases and more than 350,000 deaths each year. at present, radiotherapy is an important measure to control the recurrence of head and neck tumors, but almost all patients with head and neck squamous cell carcinoma will have acute inflammatory reactions such as radiotherapy-induced oral mucositis (riom) after radiotherapy, which seriously affects the quality of life and radiotherapy efficacy of patients. serum amyloid a1 (saa1) is an acute phase protein associated with inflammation. our previous basic research found that serum saa1 expression levels can be used as biomarkers to assess the dose received by the receptor in the early stages of radiation damage. at the same time, we confirmed that the serum level of saa1 in patients with nasopharyngeal carcinoma increased after radiotherapy. therefore, we intend to conduct a prospective, multicenter, observational study to further explore the predictive power of plasma saa1 levels for radiotherapy-induced oral mucositis, with a view to early screening and prevention of riom patients.


Eligibility criteria:
inclusion criteria: * over 18 years of age. * voluntarily sign informed consent. * the pathological diagnosis was nasopharyngeal carcinoma, head and neck tumor. * need to be treated with radiotherapy. * ecog ps score: 0/1. exclusion criteria: * there are contraindications to radiotherapy. * combined with other tumors. * patients had any serious coexisting medical conditions that could pose an unacceptable risk or negatively affect trial adherence. for example, unstable heart disease requiring treatment, chronic hepatitis, kidney disease, poor disease status, uncontrolled diabetes (fasting blood glucose \> 1.5 × uln), and mental illness. * at the investigator's discretion, those who was not considered to be suitable for participation in the study.

Keywords: saa1 radiotherapy-induced oral mucositis head and neck cancer nasopharyngeal carcinoma